细支气管肺泡癌的研究进展

肺癌在全球范围内呈上升状态，仅2005年在美国新发病者就有172000例之多。非小细胞肺癌（non-small cell lung cancer，NSCLC）占肺癌的80．0％以上。其中细支气管肺泡癌（bronchioloalveolar carcinoma，BAC）是肺腺癌的一个重要亚型，近年来BAC的发病率呈逐年上升趋势，治疗方面也取得了新的进展，是一值得重视的问题。本文就该病的流行病学、危险因子、病理学、临床表现和治疗，尤其表皮生长因子-酪氨酸激酶抑制物（epidermalgrowthfactorreceptors—tyrosinekinaseinhibitor，EGFR—TKIs）在BAC治疗方面作一综述。

Advances in bronchioloalveolar carcinoma

The incidence of lung cancer is rising worldwide.There were 172 000 newly diagnosed cases with lung cancer in 2005 in USA.Of them,more than 80.0% are non-small cell lung cancer(NSCLC).Bronchioloalveolar carcinoma(BAC) is an important subtype of pulmonary adenocarcinoma.Because of its increasing incidence and advanced treatment,BAC has attracted much attention in recent years.In this review,we will discuss the epidemiology,risk factors,pathology,clinic presentation and treatment in bronchioloalveolar cell carcinoma.Special attention is paid to the role of oral epidermal growth factor receptorstyrosine kinase inhibitors(EGFR-TKIs) in its treatment.